Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11N3O2.ClH |
| Molecular Weight | 253.685 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2
InChI
InChIKey=SOIWUULWQIKDHV-UHFFFAOYSA-N
InChI=1S/C11H11N3O2.ClH/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7;/h3-6H,2H2,1H3,(H2,13,14,16);1H
| Molecular Formula | C11H11N3O2 |
| Molecular Weight | 217.2239 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Piroximone is a nonglycoside, noncatecholamine inotropic agent. In animal experiments, it has been shown to increase cardiac contractility by mechanisms unrelated to any known receptor, acting mainly by inhibition of type III phosphodiesterase. Piroximone also possesses direct vasodilatory properties in the arterial and venous vascular bed. Piroximone combines well-balanced vasodilator and inotropic properties which make it very useful for the management of congestive heart failure. Piroximone had been in phase II clinical trial for the treatment of heart failure. However, this research has been discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity. | 2012-10-17 |
|
| Therapeutic benefit of pentostatin in severe IL-10-/- colitis. | 2008-07 |
|
| A comparison of the inotropic effects of milrinone and piroximone. | 2001-01 |
|
| Clinical pharmacokinetics of vasodilators. Part II. | 1998-07 |
|
| Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro. | 1997-10-15 |
|
| Preischemic bolus application of piroximone studied on the isolated rabbit heart--a second look including biochemical data. | 1996 |
|
| [Acute hemodynamic effects of piroximone i.v. in patients with severe heart failure]. | 1995-10 |
|
| Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP. | 1995-05-26 |
|
| Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of rat cardiac myofibrils. | 1995-05 |
|
| Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency. | 1995-02 |
|
| Metabolism and pharmacokinetics of the cardiotonic agent piroximone and of its major metabolite in dog. | 1995-01 |
|
| Determination of piroximone in human plasma by high-performance liquid chromatography. | 1994-10 |
|
| Effects of piroximone on the right ventricular function in severe heart failure patients. | 1994-05 |
|
| Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure. | 1994-04 |
|
| [Continuous monitoring of cardiac output by analysis of the pulse contour]. | 1994-01 |
|
| Postischemic hemodynamic changes after piroximone administration in isolated rabbit heart. | 1994 |
|
| Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery. | 1993-12 |
|
| Circulatory effects of the PDE-inhibitors piroximone and enoximone. | 1993-10 |
|
| Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure. | 1993-03 |
|
| The influence of clinical intervention on pressure-volume relationships--the conductance (volume) technique. | 1992-11 |
|
| Acute hemodynamic effects of MDL 19205 in mild congestive heart failure. | 1987-02 |
|
| Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systems. | 1984-01-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:55:42 GMT 2025
by
admin
on
Mon Mar 31 17:55:42 GMT 2025
|
| Record UNII |
55MSM9KE7O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23623017
Created by
admin on Mon Mar 31 17:55:42 GMT 2025 , Edited by admin on Mon Mar 31 17:55:42 GMT 2025
|
PRIMARY | |||
|
55MSM9KE7O
Created by
admin on Mon Mar 31 17:55:42 GMT 2025 , Edited by admin on Mon Mar 31 17:55:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |